Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
01 mai 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
29 avr. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
11 avr. 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Two Upcoming Investor Conferences
05 mars 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
04 mars 2019 16h18 HE
|
Otonomy, Inc.
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase 1/2 trial in hearing...
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
25 févr. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Provides Corporate and Product Pipeline Update
03 janv. 2019 07h30 HE
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) --...
Otonomy to Present at the J.P. Morgan Healthcare Conference
02 janv. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference
15 nov. 2018 08h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David...
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
06 nov. 2018 07h30 HE
|
Otonomy, Inc.
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company...